Post-HSCT Maintenance Treatment Using Entrectinib for an AML Patient Accompanied with ETV6::NTRK3: A Case Report
Xiaoli Zhao,1,2 Mengze Hao,1,2 Xiaoyu Zhang,1,2 Jialin Wei,1,2 Sizhou Feng,1,2 Yi He,1,2 Erlie Jiang,1,2 Mingzhe Han1,2 1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseas...
Main Authors: | Zhao X, Hao M, Zhang X, Wei J, Feng S, He Y, Jiang E, Han M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-12-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/post-hsct-maintenance-treatment-using-entrectinib-for-an-aml-patient-a-peer-reviewed-fulltext-article-OTT |
Similar Items
-
Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report
by: Dan Li, et al.
Published: (2024-04-01) -
Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer
by: Etsuko Moriyama, et al.
Published: (2023-08-01) -
A case of thyroid carcinoma with mucinous features harboring ETV6-NTRK3 fusion: Expanding the morphologic spectrum of NTRK-rearranged thyroid carcinoma
by: Khaled A. Murshed, et al.
Published: (2022-06-01) -
Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
by: Chiara Lazzari, et al.
Published: (2022-11-01) -
MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
by: Yohei Takumi, et al.
Published: (2023-03-01)